NanoRepro AG Converts License to Equity Stake in FiberSense

NanoRepro AG has announced the conversion of its CGM-distribution license into an equity stake in FiberSense, a healthcare technology company specializing in continuous glucose monitoring (CGM) systems. This development follows FiberSense receiving CE certification for its CGM system, setting the stage for commercial market entry.

The potential market for CGM technology is promising, with expected growth from $15.3 billion in 2026 to $31.4 billion by 2031, according to Mordor Intelligence. NanoRepro's transaction includes a €1 million convertible bond to support the market launch, which could occur within a year.

NanoRepro sees this as an opportunity to capitalize on FiberSense's commercial prospects. Transaction terms suggest a potential value creation for NanoRepro, possibly significant relative to its market capitalization.